For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

We reviewed hundreds of skin care and makeup products to bring you the best of Shop TODAY's 2024 Beauty Awards. From skin ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...

Sana Biotechnology (SANA) announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass compared ...

Late consumption of calories is associated with worse glucose tolerance, according to a study published online Oct. 2 ...

A study of 116 clinical trials found that to achieve significant weight loss, people need to commit to at least 150 minutes ...

Lucknow: Contrary to the popular belief that black coffee and green team contract blood sugar and improve insulin sensitivity ...

Type 1 diabetes (T1D) is a metabolic disorder caused by a complete lack of insulin, primarily manifested by hyperglycemia. The mechanisms underlying the onset of T1D are complex, involving genetics, ...